Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?